Nima Motamed1, Behnam Rabiee2, Hossein Poustchi3, Babak Dehestani4, Gholam Reza Hemasi5, Mahmood Reza Khonsari6, Mansooreh Maadi7, Fatemeh Sima Saeedian8, Farhad Zamani9. 1. Department of Social Medicine, Zanjan University of Medical Sciences, Gavazang Road, Zanjan 45139-56184, Iran. Electronic address: nima.motamed@gmail.com. 2. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: behnam.rabiee@gmail.com. 3. Digestive Diseases Research Institute (DDRI), Shariati Hospital, Tehran University of Medical Sciences, Kargar Shomali Ave, Tehran 14117-13135, Iran. Electronic address: h.poustchi@gmail.com. 4. Center for Cardiovascular Research, Washington University in Saint Louis School of Medicine, 660 South Euclid Avenue, Campus Box 8086, Saint Louis, MO 63110, USA. Electronic address: bdehestani@dom.wustl.edu. 5. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: hemmasi46@yahoo.com. 6. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: khonsarimahmoodreza@gmail.com. 7. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: maadi_mansooreh@yahoo.com. 8. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: fs_saeedian@yahoo.com. 9. Department of Gastroenterology and Liver Disease, Gastrointestinal and Liver Disease Research Center (GILDRC), Tehran Firoozgar Hospital, Iran University of Medical Sciences, Beh Afarin St., Karim Khan Zand Ave, Tehran 15900, Iran. Electronic address: zamani.farhad@gmail.com.
Abstract
BACKGROUND AND AIMS: The association between cardiovascular diseases (CVD) and non-alcoholic fatty liver disease (NAFLD) was confirmed by a large body of evidence. This study was conducted to determine the association between NAFLD and 10-year CVD risk. METHODS: This study utilized the data of 2804 subjects aged 40-74 years from a cohort study of northern Iran. Two CVD risk assessment tools, American College of Cardiology/American Heart Association and Framingham general cardiovascular risk profile for use in primary care, were utilized to determine the 10-year CVD risk in patients with NAFLD and the individuals without this condition. The mean risks were compared between these two groups. RESULTS: Using ACC/AHA approach, the mean risk in male participants suffering NAFLD was 14.2%, while in men without NAFLD was 11.7% (P-value < 0.0001). Using Framingham approach, the mean risks were 16.0 and 12.7% in men with and without NAFLD, respectively (P-value < 0.0001). Using ACC/AHA approach, the mean risks in female participants with and without NAFLD were 6.7 and 4.6%, respectively (P-value < 0.0001). Applying Framingham approach, the mean risk was 8.2% in women with NAFLD and 5.4% in women without NAFLD (P-value < 0.0001). CONCLUSION: The individuals with NAFLD had a higher risk of 10-year CVD events than individuals without NAFLD, according to both ACC/AHA tool and primary care version of Framingham tool. A large proportion of NAFLD patients fulfill the criteria of statin therapy recommendation, suggesting that statin therapy could reduce 10-year CVD risk in NAFLD patients.
BACKGROUND AND AIMS: The association between cardiovascular diseases (CVD) and non-alcoholic fatty liver disease (NAFLD) was confirmed by a large body of evidence. This study was conducted to determine the association between NAFLD and 10-year CVD risk. METHODS: This study utilized the data of 2804 subjects aged 40-74 years from a cohort study of northern Iran. Two CVD risk assessment tools, American College of Cardiology/American Heart Association and Framingham general cardiovascular risk profile for use in primary care, were utilized to determine the 10-year CVD risk in patients with NAFLD and the individuals without this condition. The mean risks were compared between these two groups. RESULTS: Using ACC/AHA approach, the mean risk in male participants suffering NAFLD was 14.2%, while in men without NAFLD was 11.7% (P-value < 0.0001). Using Framingham approach, the mean risks were 16.0 and 12.7% in men with and without NAFLD, respectively (P-value < 0.0001). Using ACC/AHA approach, the mean risks in female participants with and without NAFLD were 6.7 and 4.6%, respectively (P-value < 0.0001). Applying Framingham approach, the mean risk was 8.2% in women with NAFLD and 5.4% in women without NAFLD (P-value < 0.0001). CONCLUSION: The individuals with NAFLD had a higher risk of 10-year CVD events than individuals without NAFLD, according to both ACC/AHA tool and primary care version of Framingham tool. A large proportion of NAFLD patients fulfill the criteria of statin therapy recommendation, suggesting that statin therapy could reduce 10-year CVD risk in NAFLD patients.